Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Abivax    ABVX   FR0012333284

ABIVAX

(ABVX)
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
10/11/2019 10/14/2019 10/15/2019 10/16/2019 10/17/2019 Date
8(c) 8.03(c) 8(c) 8.05(c) 7.96 Last
2 438 3 576 3 480 3 859 4 822 Volume
-1.48% +0.37% -0.37% +0.63% -1.12% Change
More quotes
Financials (EUR)
Sales 2019 -
EBIT 2019 -16,1 M
Net income 2019 -12,6 M
Finance 2019 11,4 M
Yield 2019 -
Sales 2020 82,4 M
EBIT 2020 54,0 M
Net income 2020 49,7 M
Finance 2020 24,4 M
Yield 2020 -
P/E ratio 2019 -4,19x
P/E ratio 2020 0,89x
EV / Sales2019 -
EV / Sales2020 0,85x
Capitalization 94,7 M
More Financials
Company
ABIVAX is a biotechnology company specializing in immune system targeting for viral diseases. The group operates three technological platforms: ?antiviral', ?immune stimulation' and ?polyclonal antibody' platform. The most advanced product, ABX464, is currently in Phase II clinical trial to assess... 
More about the company
Latest news on ABIVAX
09/30ABIVAX : 2019 Half-Year Financial Report
PU
09/19ABIVAX : Half-year results
CO
08/19ABIVAX : First patient enrolled in Abivax ABX464-103 Phase 2b Clinical Trial in ..
PU
07/11ABIVAX : Completes €12 Million Capital Raise Entirely Subscribed by Sofinnova Pa..
PU
05/16ABIVAX : secures FDA approval for Phase I/II trial with ABX196 in HCC
AQ
05/15ABIVAX : Registration Document 2019 (EN)
PU
05/14ABIVAX : and Scripps Research Announce FDA Approval to Initiate a Phase 1/2 Clin..
AQ
05/03ABIVAX : receives Phase IIb trial authorisation from Canada for ABX464
AQ
03/14ABIVAX : Annual results
CO
03/11ABIVAX SA : annual earnings release
2018ABIVAX : Pr_abivax_ecco_20122018
PU
2018ABIVAX : Half-year results
CO
2018ABIVAX SA : half-yearly earnings release
2018ABIVAX : Completes Dosing in Phase 2a Proof-of-Concept Clinical Trial of ABX464 ..
PU
2018ABIVAX : announces the publication of its 2018 Registration Document
PU
More news
News in other languages on ABIVAX
10/10EN DIRECT DES MARCHES : LVMH, Casino, Edenred, DBV Technologies, Renault, UCB..
10/10ABIVAX : invité à la semaine UEG (United European Gastroenterology) 2019
10/10BIOTECH TIME : DBV et Valbiotis lèvent des capitaux, AB Science change un rendez..
10/10STOCK MARKET PARIS : Tout et son contraire
10/09ABIVAX : Number of Shares and Vote Rights - September 2019
More news
Analyst Recommendations on ABIVAX
More recommendations
Sector news : Biotechnology & Medical Research - NEC
10/16INCYTE : Says Phase 3 REACH2 Trial Meets Endpoint
DJ
10/15New Gilead Sciences CFO Expected to Pursue More Deals to Expand Portfolio
DJ
10/15GILEAD SCIENCES : Names Andrew Dickinson Chief Financial Officer
DJ
10/10GILEAD SCIENCES : Galapagos See Efficacy in Advanced Rheumatoid Arthritis Study
DJ
10/10Reata Pharmaceuticals Shares Up 8% on Re-Acquiring Bardoxolone Rights
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart ABIVAX
Duration : Period :
Abivax Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABIVAX
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 21,65  €
Last Close Price 8,05  €
Spread / Highest target 289%
Spread / Average Target 169%
Spread / Lowest Target 52,8%
EPS Revisions
Managers
NameTitle
Hartmut J. Ehrlich Chief Executive Officer
Philippe Pouletty Chairman
Didier Blondel Chief Financial Officer & Secretary
Didier Scherrer Vice President-Research & Development
Jean-Marc Steens Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABIVAX-32.01%105
IQVIA HOLDINGS INC.24.67%28 371
LONZA GROUP33.45%25 332
CELLTRION, INC.--.--%20 127
INCYTE CORPORATION22.85%16 801
SEATTLE GENETICS, INC.48.01%14 251